INDV
Indivior Pharmaceuticals, Inc.
Stock
$35.71+0.33 (+0.93%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $1.3B | $1.2B | $1.2B | $1.1B | $901M | $791M |
| Cost of revenue | $239M | $245M | $231M | $174M | $152M | $127M |
| Gross profit | $1.1B | $994M | $957M | $919M | $749M | $664M |
| R&D | $82M | $97M | $107M | $116M | $74M | $52M |
| SG&A | $590M | $634M | $612M | $565M | $466M | $431M |
| Other operating expenses | — | — | $200M | $390M | $286M | — |
| Operating income | $421M | $262M | $38M | −$152M | −$77M | $213M |
| Non-operating income | −$28M | −$23M | −$18M | $7.0M | −$9.0M | −$23M |
| Pretax income | $393M | $239M | $20M | −$145M | −$86M | $190M |
| Taxes | $38M | $29M | $13M | −$19M | −$44M | −$15M |
| Net income | $355M | $210M | $7.0M | −$126M | −$42M | $205M |
| Diluted EPS | $2.77 | $1.64 | $0.05 | −$0.92 | −$0.30 | — |
| Diluted shares | — | 128.0M | 133.0M | 137.0M | 139.0M | 151.9M |
| Revenue growth | — | +4.3% | +8.7% | +21.3% | +13.9% | — |
| Gross margin | 82.1% | 80.2% | 80.6% | 84.1% | 83.1% | 83.9% |
| Operating margin | 31.6% | 21.1% | 3.2% | −13.9% | −8.5% | 26.9% |
| Net margin | 26.7% | 16.9% | 0.6% | −11.5% | −4.7% | 25.9% |